Use Of Opioids For Pain Management In Nursing Homes: A Dissertation, 2015 University of Massachusetts Medical School
Use Of Opioids For Pain Management In Nursing Homes: A Dissertation, Camilla B. Pimentel
GSBS Dissertations and Theses
Nursing homes are an essential yet understudied provider of cancer-related care for those with complex health needs. Nine percent of nursing home residents have a cancer diagnosis at admission, and it is estimated that one-third of them experience pain on a daily basis. Although pain management is an essential component of disease treatment, few studies have evaluated analgesic medication use among adults with cancer in this setting. Use of opioids, which are the mainstay of pain management in older adults because of their effectiveness in controlling moderate to severe pain, may be significantly related to coverage by the Medicare Part ...
Orphan Drug Development: Incentives Under The Orphan Drug Act, 2015 Trinity College
Orphan Drug Development: Incentives Under The Orphan Drug Act, Sara H D Smith
Senior Theses and Projects
After describing the intellectual property and regulatory environment for orphan drugs in the United States, this thesis compares the investment decisions in the orphan drug market with the larger pharmaceutical industry. A series of case studies trace the development paths of different orphan products using information collected through the Food and Drug Administration (FDA) Approved Drug Product and Orphan Drug Product Designation Databases. In addition to this analysis, difference-in-differences estimates calculated using annual revenues compare the relative success of different orphan products under the current incentive system. This study finds that partial orphan drugs are associated with larger revenue growth ...
One State's Perspective On The Management Of Hepatitis C Drugs, 2015 University of Massachusetts Medical School
One State's Perspective On The Management Of Hepatitis C Drugs, Pavel Lavitas
Commonwealth Medicine Publications
This presentation provides an overview of the hepatitis C virus monitoring program implemented for state Medicaid to contain costs and to promote optimal member care. Key clinical and economic outcomes of the monitoring program are highlighted and formulary management strategies for novel hepatitis C virus agents identified.
Presented at the American Drug Utilization Review Society 2015 Conference.
Reimbursement For Pharmaceutical Care Services: The California Experience, 2015 Chapman University
Reimbursement For Pharmaceutical Care Services: The California Experience, Jeffery A. Goad, Kathleen Johnson, Michael Rudolph
"While it is true that pharmacists are changing their practice habits, they are doing so for the betterment of their patients’ drug therapy outcomes and the healthcare system. The pharmacist serves as the vital link between the patient, physician, and healthcare system. By working with patients and physicians, pharmacists have demonstrated in the literature that they can improve patient drug therapy outcomes, thus preventing unnecessary healthcare expenditures (Fincham, 1998). Pharmacists have long been held in highest esteem by patients, being voted the number one trusted professional for 10 consecutive years. The evidence is clear that pharmacists provide a valuable service ...
Medication Misadventures: The Case Of Benzodiazepines, 2015 University of Kentucky
Medication Misadventures: The Case Of Benzodiazepines, Sarah E. Wixson
Theses and Dissertations--Pharmacy
For patients afflicted with symptoms of anxiety and insomnia, benzodiazepines are generally a safe and effective short-term pharmacological treatment option. Although considered safer than other sedative-hypnotic medications, substantial concern exists regarding the addictive nature and abuse potential of benzodiazepines along with potentially inappropriate prescribing and utilization in clinically vulnerable populations. These medication misadventures can have a significant impact on public health. Examples of medication misadventures as they pertain to benzodiazepines include the prescribing and use in clinically vulnerable populations for whom they are contraindicated or their efficacy has not been evaluated, the development of tolerance or addiction, abuse of the ...
Economic Impact Of Waste In Prescribing, Dispensing, And Medication Consumption In The United States, 2015 Virginia Commonwealth University
Economic Impact Of Waste In Prescribing, Dispensing, And Medication Consumption In The United States, Sarah Almanie
Theses and Dissertations
ECONOMIC IMPACT OF WASTE IN PRESCRIBING, DISPENSING, AND MEDICATION CONSUMPTION IN THE UNITED STATES
By Sarah A. Almanie, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2015.
Major Director: David A. Holdford, R.Ph., M.S., Ph.D., FAPhA
Department of Pharmacotherapy and Outcomes Science
OBJECTIVES: This research examines waste associated with the medication use process which consists of unfilled prescriptions, abandoned prescriptions, or unused prescription medications. The aim of this study is to quantify the direct medical costs of medication ...
The Effect Of Any Willing Provider And Freedom Of Choice Laws On Prescription Drug Expenditures, 2015 University of Pennsylvania Carey Law School
The Effect Of Any Willing Provider And Freedom Of Choice Laws On Prescription Drug Expenditures, Jonathan Klick, Joshua D. Wright
Faculty Scholarship at Penn Law
Any Willing Provider and Freedom of Choice laws restrict the ability of managed care entities, including pharmacy benefit managers, to selectively contract with providers. The managed care entities argue this limits their ability to generate cost savings, while proponents of the laws suggest that such selective contracts limit competition, leading to an increase in aggregate costs. We examine the effect of state adoption of such laws on total state healthcare spending, finding that any willing provider/freedom of choice laws are associated with cost increases of at least 3 percent. These results suggest that these laws are harmful from a ...
The Health Effects Of Increased Cvd Medication Use Varies By Cvd Status Of Medicare Beneficiaries, 2014 University of Massachusetts Medical School
The Health Effects Of Increased Cvd Medication Use Varies By Cvd Status Of Medicare Beneficiaries, Hassan Fouayzi, Arlene Ash, Allison B. Rosen
UMass Center for Clinical and Translational Science Research Retreat
Background/Aims: Cardiovascular disease (CVD) is the leading cause of death and disability in the United States. The aim of this study was to assess the effect of increased utilization of CVD medications on MI, stroke, and all-cause mortality among different CVD risk subgroups.
Methods: We used 1999-2009 Medicare Current Beneficiary Survey data to identify 26,903 non-institutionalized, fee-for-Service Medicare beneficiaries 65 years or older who were users of angiotensin converting enzyme inhibitor (ACE), angiotensin receptor blocker (ARB), other antihypertensive medications, and statin. These beneficiaries contributed a total of 61,741 person-years. For each study drug, we used logistic regression ...
Effects Of Increased Utilization Of Cvd Medications By Medicare Beneficiaries On Spending Vary By Cvd Status, 2014 University of Massachusetts Medical School
Effects Of Increased Utilization Of Cvd Medications By Medicare Beneficiaries On Spending Vary By Cvd Status, Hassan Fouayzi, Arlene Ash, Allison B. Rosen
UMass Center for Clinical and Translational Science Research Retreat
Background/Aims: To understand the value of our substantial investment in cardiovascular disease (CVD) care, it is important to understand the associations of CVD therapies and spending. The aim of this study was to assess the effect of increased utilization of CVD medications on spending among different CVD risk subgroups.
Methods: We used 1999-2009 Medicare Current Beneficiary Survey data to identify 26,903 non-institutionalized, fee-for-Service 65 years or older users of angiotensin converting enzyme inhibitor (ACE), angiotensin receptor blocker (ARBs), other antihypertensives, and statins(61,741person-years). For each drug, we used generalized linear models to estimate the effect of additional ...
Big Pharma And Big Medicine In The Global Environment, 2014 Loyola University Chicago
Big Pharma And Big Medicine In The Global Environment, Anne E. Figert, Susan E. Bell
Sociology: Faculty Publications and Other Works
In previous work we argued that sociologists need to expand our thinking about pharmaceuticalization, the process of understanding and/or treating social, behavioral, or bodily conditions with pharmaceuticals. The majority of sociological scholarship has investigated pharmaceuticalization as a primarily Western process and conceptualized it in modern terms (Bell and Figert 2010, 2012a, 2012b). In our view, the work of anthropologists and science and technology studies (STS) scholars who decenter the West as the starting point for research opens up new avenues for understanding the global dynamics of pharmaceuticalization. We have also argued in favor of adopting a postmodern theoretical lens ...
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, 2014 University of New Hampshire School of Law
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Law Faculty Scholarship
Despite increasing recalls, contamination events, and shortages, drug companies continue to rely on outdated manufacturing plants and processes. Drug manufacturing’s inefficiency and lack of innovation stand in stark contrast to drug discovery, which is the focus of a calibrated innovation policy that combines patents and FDA regulation. Pharmaceutical manufacturing lags far behind the innovative techniques found in other industries due to high regulatory barriers and ineffective intellectual property incentives. Among other challenges, although manufacturers tend to rely on trade secrecy because of the difficulty in enforcing patents on manufacturing processes, trade secrecy provides limited incentives for innovation. To increase ...
Evaluating Albumin Utilization In A Community-Based Hospital Post-Hetastarch Food And Drug Administration (Fda) Warning, Wilbert Fuerte, Frances Ordieres, Judy Tseng
No abstract provided.
Implications Of Dose‐Rounding Intravenous Chemotherapy At A Community‐Based Hospital, 2014 Homestead Hospital
Implications Of Dose‐Rounding Intravenous Chemotherapy At A Community‐Based Hospital, Wilbert Fuerte, Omi Gopalani, Judy Tseng
No abstract provided.
Pharmaceutical Counterfeiting And The Rfid Technology Intervention, 2013 Marshall University
Pharmaceutical Counterfeiting And The Rfid Technology Intervention, Alberto Coustasse, Cody Arvidson, Phil Rutsohn
Alberto Coustasse, DrPH, MD, MBA, MPH
Both nationally and internationally, pharmaceutical counterfeiting has become a problem that is threatening economic stability and public health. The purpose of the present research study review was to analyze the scope and severity of pharmaceutical counterfeiting and to establish if the implantation of the Radio Frequency Identification Device (RFID) model can more efficiently be used within the pharmaceutical supply chain to reduce the problem counterfeit drugs impose on public health and international economic stability. Results indicated that implementing the RFID model for tracking drugs at the item level in the pharmaceutical supply chain has potential to alleviate the scope of ...
Dynamic Cost-Effectiveness Of Oncology Drugs, 2012 Harbor UCLA Medical Center
Dynamic Cost-Effectiveness Of Oncology Drugs, Yang Lu, John Penrod, Neeraj Sood, Saarah Woodby, Tomas Philipson
Objective: To develop a methodology for computing cost-effectiveness measures of a drug throughout its life cycle.
Study Design: We developed a set of models that measure the long-term cost-effectiveness of 2 oncology drugs, paclitaxel and docetaxel, throughout their life cycles.
Methods: The study combined pricing history of the drugs, US Food and Drug Administration approval dates, drug utilization from Medicare claims, and clinical effectiveness information from phase III studies reported in the scientific literature. These data were used to estimate the incremental cost-effectiveness ratio (ICER) at the time of market entry and by year thereafter. The study population included patients ...
Cost Of Capital For Pharmaceutical, Biotechnology, And Medical Device Firms, 2012 University of Pennsylvania
Cost Of Capital For Pharmaceutical, Biotechnology, And Medical Device Firms, Scott E. Harrington
Health Care Management Papers
This article provides new estimates of systematic risk and the cost of equity capital for the pharmaceutical, biotechnology, and medical device sectors. The main analysis employs data for pharmaceutical, biotechnology, and medical device firms with publicly traded stock on US exchanges (including foreign-owned firms) with at least $100 million of market capitalization during the periods 2001–2005 and 2006–2008. Two frameworks are used for estimating firms' risk and the cost of equity capital: the capital asset pricing model (CAPM) and the empirically driven three risk-factor model of Fama and French (the F-F model). The article is organized as follows ...
Recession Proof Pills: An Examination Of The Relationship Between Recession Economics And Pharmaceutical Expenditures, Kevin Gray
Annual Undergraduate Conference on Health and Society
The first decade of the 21st century proved to be a time of turbulence and volatility in the worldwide economy. Oddly enough, even as Americans’ disposable income decreased, spending on health care steadily increased. Americans spent $249.9 billion on prescription drugs in 2009, contrasted against $120.9 billion in 2000—a 105% increase.1 We may question the overall ramifications of such increases in pharmaceutical sales and the correlation to other economic factors. That is, how was the pharmaceutical sector able to boast gains when the housing market collapsed? One answer is that people place a priority on their ...
Pharmaceutical Strategy And The Evolving Role Of Merger And Acquisition, 2012 University of Pennsylvania
Pharmaceutical Strategy And The Evolving Role Of Merger And Acquisition, Lawton R. Burns, Sean Nicholson, Joanna P. Wolkowski
Health Care Management Papers
It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is the most adaptable to change.
The sections in this chapter deal with a common set of topics: horizontal consolidation, merger and acquisition (M&A), advantages of size, economies of scale and scope, diversification, and industry concentration. These topics all interrelate around the fundamental issue in industrial organization: how best to organize firms and markets in order to achieve optimal economic performance?
Consolidation has been rampant in most sectors of the healthcare industry since the 1980s and 1990s ...
Reliability And Credibility Of Progress Test Criteria, Developed By Alumni, Faculty, And Mixed Alumni-Faculty Judge Panels, H. Glenn Anderson Pharmd, Arthur A. Nelson Phd
Pharmacy Practice & Administration
Objective. To compare the reliability and credibility of Angoff-based, absolute criteria derived by faculty, alumni, and a combination of alumni and faculty judge panels.
Methods. Independently, faculty, alumni, and mixed faculty-alumni judge panels developed pass/fail criteria for an 86-item test. Generalizability and decision studies were performed. Root mean square errors (RMSE) and 95% confidence intervals were calculated for reliability and credibility assessment. School graduate performance upon the North American Licensure Examination (NAPLEX) was the comparator for credibility assessment.
Results. RMSEs were 1.06%, 1.42%, and 2.32% for the alumni, faculty, and mixed judge panels respectively. The school ...
Side Effects Of Competition: The Role Of Advertising And Promotion In Pharmaceutical Markets, 2011 University of Pennsylvania
Side Effects Of Competition: The Role Of Advertising And Promotion In Pharmaceutical Markets, Guy David, Sara Markowitz
Health Care Management Papers
The extent of pharmaceutical advertising and promotion can be characterized by a balancing act between profitable demand expansions and potentially unfavorable subsequent regulatory actions. However, this balance also depends on the nature of competition (e.g. monopoly versus oligopoly). In this paper we model the firm's behavior under different competitive scenarios and test the model's predictions using a novel combination of sales, promotion, advertising, and adverse event reports data. We focus on the market for erectile dysfunction drugs as the basis for estimation. This market is ideal for analysis as it is characterized by an abrupt shift in ...